ETH 155008
Alternative Names: ETH-155008Latest Information Update: 28 Jul 2024
At a glance
- Originator Shengke Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Fms-like tyrosine kinase 3 inhibitors; PIM3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Australia (PO, Tablet)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in Australia (PO, Tablet)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in Australia (PO, Tablet)